Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Elironrasib · RMC-6291

Small molecule · Inhibitor of KRAS G12C (KRAS) · developed by Revolution Medicines

Phase 1/2 Most advanced trial
1 Registered trials

What is Elironrasib?

Elironrasib is an orally bioavailable covalent inhibitor of KRAS G12C that forms a tri-complex with cyclophilin A and the mutant KRAS protein to inhibit GTP-bound KRAS signaling. It is being studied in advanced and metastatic solid tumors, including non-small cell lung cancer and colorectal cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
RMC-6291
Drug type
Small molecule
Targets
KRAS G12C (KRAS), cyclophilin A (PPIA) (binding partner it blocks)
Mechanism
Inhibitor of KRAS G12C (KRAS)
Pathways
KRAS signaling, MAPK/ERK, PI3K/Akt
Therapy area
Oncology
Developer
Revolution Medicines, Inc.
In trials of
SMMT
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
942KVV5CJP

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07397338 Phase 1/2 Advanced Solid Tumors Recruiting SMMT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid TumorsColorectal Cancer (CRC)CRCMetastatic Solid TumorsNon-small Cell Lung Cancer (NSCLC)NSCLC

Other drugs acting on KRAS

Sotorasib FDA approved AN9025 Phase 1 ARV-806 Phase 1/2 Calderasib Phase 3 ERAS-0015 Phase 1 Olomorasib Phase 3 Zoldonrasib Phase 1/2

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.